Drug Franchises
Executive Summary
Franchises can create scale for large and mid-sized drug companies alike. But few firms have really created these customer-driven alternatives to size-for-size's sake. Franchises need to be built up from an understanding of and relationships with the complex set of customers and suppliers in a particular field of specialization and should only be built where such a customer group truly exists.
You may also be interested in...
The New Face Of Blockbuster Drugs
Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.
The New Face Of Blockbuster Drugs
Blockbuster drugs are not going away but as science and market conditions continue to evolve and unmet needs shift to new territories, their profile is likely to change again. Companies can use strategies to offset the potential shortcomings of the new blockbuster model and improve their chances of becoming the successful players of tomorrow.
Schering: Addressing the Specialist Challenge
As a large yet specialist firm, Schering must compete in multiple areas. That means developing and marketing differentiated products across a number of fronts--and dealing with the lower-than-average margins that typically come with mixed portfolios. How well the German group overcomes these challenges should be of growing interest to Big Pharma, given the risks of relying on blockbusters.